Editas Medicine, Inc.
Financials
Valuation Metrics
Editas Medicine, Inc.'s Market Cap is $415M. At end of 2025 it was $182M. Ranked #2857 of 3,121 in US market (top 92%), #1267 of 1,463 on NASDAQ (top 87%), #230 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 86%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $415M | US#2,857/3,121 Sec#230/266 |
| Revenue | $47M | US#2,780/3,121 Sec#153/266 |
| Net Income | $-74M | US—/3,121 Sec—/266 |
| Total Assets | $237M | US#2,967/3,121 Sec#236/266 |
| Net Assets | $105M | US#2,805/3,121 Sec#214/266 |
| Employees | 87 | US#2,655/3,121 Sec#188/266 |
| Value | ||
| P/B | 3.94x | US#2,011/3,121 Sec#116/266 |
| P/S | 8.82x | US#2,649/3,121 Sec#109/266 |
| FCF Yield | -29.07% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -70.24% | US#2,753/3,121 Sec#186/266 |
| ROA | -31.15% | US#2,892/3,121 Sec#157/266 |
| Op. Margin | -174.71% | US#2,764/3,121 Sec#133/266 |
| Revenue Growth | 20.83% | US#660/3,121 Sec#75/266 |
| Financial Health | ||
| Debt Ratio | 125.46% | US#1,306/3,121 Sec#175/266 |
| Total Debt | $16M | US#2,793/3,121 Sec#196/266 |
| FCF | $-121M | US#2,675/3,121 Sec#159/266 |
| Cash | $182M | US#1,811/3,121 Sec#119/266 |
| Current Ratio | 3.19x | US#739/3,121 Sec#185/266 |
| Performance | ||
| 1Y Return | -10.00% | US#1,810/3,121 Sec#182/266 |
| 1M Return | -16.92% | US#1,814/3,121 Sec#145/266 |
| From 52W High | -40.53% | US#2,465/3,121 Sec#193/266 |
| 1Y MDD | -59.76% | US#2,774/3,121 Sec#214/266 |
| Trading | ||
| Volume | 14,083,020 shares | US#487/3,121 Sec#41/266 |
| Trading Value | $39M | US#2,363/3,121 Sec#193/266 |
| Per Share | ||
| EPS | $-0.48 | US—/3,121 Sec—/266 |
| BPS | $0.69 | US#2,738/3,121 Sec#213/266 |
Company Info
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.